| Drug Type Monoclonal antibody | 
| Synonyms- | 
| Action inhibitors | 
| Mechanism CXCL1 inhibitors(C-X-C motif chemokine ligand 1 inhibitors), CXCL2 inhibitors(C-X-C motif chemokine ligand 2 inhibitors), CXCL3 inhibitors(C-X-C motif chemokine ligand 3 inhibitors) + [1] | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 








| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | Japan  | 05 Nov 2024 | 






